Le Lézard
Classified in: Health, Science and technology, Business
Subject: TRI

Innovent Reports Oncology Pipeline Updates at Investor Meeting


SAN FRANCISCO and SUZHOU, China, June 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, provided updates on its oncology pipeline at an investor meeting. At several major international oncology annual meetings this year, Innovent presented clinical data on multiple cancer drug candidates, including 10 oral reports and over 15 posters. In a conference call with investors on June 17, Innovent interpreted the clinical data for these drugs in detail. The company also outlined its current R&D strategy centered on global innovation, as well as the early research mechanisms, development strategies and future directions for multiple mid- and early-stage molecular candidates in its pipeline. Innovent's Chief Financial Officer Rachel You, Senior Vice President of Oncology Development Dr. Hui Zhou, and Vice President of Oncology Biology and ADC Drug Research Dr. Kaijie He attended the meeting and made reports.

Oncology pipeline development strategy: extensively deploy "IO + ADC" to solve unmet clinical needs worldwide

Scientific and technological advancements have steadily increased cancer patient survival rates and quality of life. However, many unmet clinical needs persist in cancer treatment. These include the limited response rates to immunotherapies like PD-1, with most responses resulting in relapse or resistance. Additionally, the effectiveness of current mainstream treatment, such as anti-angiogenic drugs, remains limited. Significant unmet needs continue to drive further innovation in oncology drug development.

Innovent has built a product pipeline of 36 new drug candidates, including 22 in oncology. Utilizing a world-leading antibody technology platform, differentiated linker-payloads and deep scientific expertise in oncology, Innovent has extensively deployed a combination of immune-oncology (IO) and antibody-drug conjugates (ADCs). This comprehensive "IO + ADC" approach aims to drive global innovation and enhance the brand positioning for the Company's oncology pipeline, which strives to "further life's possibilities."

Key product milestones: PoC + MRCT driving the globalization of innovative therapies

The Company is progressing its innovative oncology pipeline through clinical proof-of-concept (PoC) studies and global multi-regional clinical trials (MRCT). Several high-potential molecules have now entered clinical development, including the three novel candidates IBI363, IBI343 and IBI389, which were discussed in detail on the call. Innovent also has additional bispecific antibody and ADC candidates advancing in early global clinical development.

IBI363: First-in-class PD-1/IL-2 ?-bias bispecific antibody fusion protein shows promising anti-tumor efficacy across multiple cancer types, including in immunotherapy-treated and 'cold' tumors, signaling the emergence of a potential next-generation IO therapy

Two CLDN18.2-target based innovative technology modalities, IBI343 and IBI389, showed initial breakthrough efficacy

IBI343: Innovative TOPO1i CLDN18.2 ADC, the world's first ADC drug to show initial breakthrough efficacy in pancreatic cancer

IBI389 (anti-CLDN18.2/CD3 bispecific antibody): First-in-class T-cell engager with anti-tumor activity observed in pancreatic cancer

Looking ahead, Innovent will continue to advance the high-quality clinical development of its oncology product line, address unmet medical needs in cancer treatment and promote global innovation guided by its "IO + ADC" strategy.

Dr. Hui Zhou, Senior Vice President of Oncology Development at Innovent Biologics, said: "As one of the few biopharmaceutical companies with leading R&D capabilities in both IO and ADC, we possess a unique competitive advantage in next-generation oncology treatment innovations. We will adhere to our mission of empowering patients worldwide with affordable, high-quality biopharmaceuticals, aiming to benefit even more patients and support the Healthy China 2030 initiative."

Detailed sharing materials can be downloaded from the company's official website, link: https://investor.innoventbio.com/cn/investors/webcasts-and-presentations/

About Innovent Biologics:

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 10 products in the market. It has 4 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

SOURCE Innovent Biologics


These press releases may also interest you

at 06:05
Biodesix, Inc. , a leading diagnostic solutions company, announced today that it will release financial results for the second quarter ended June 30, 2024 after the close of trading on Wednesday, August 7. Biodesix management will host a conference...

at 06:05
ICON plc , a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed...

at 06:05
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion. Second quarter...

at 06:00
Paragon Health Institute, a leader in health care research and market-based policy recommendations, has released a proposal for Medicaid finance reform. At the heart of the proposal is correcting the flawed federal medical assistance percentage...

at 05:45
The global pediatric cardiology market is projected to total a valuation of nearly US$ 4.3 billion in 2024. During the forthcoming forecast period, the ecosystem is...

at 05:15
The micropump market was projected to attain US$ 1.9 billion in 2023. It is likely to garner an 18.7% CAGR from 2024 to 2034, and by 2034, the market is expected to attain US$ 12.4 billion.  Innovations in micropump technologies, including the...



News published on and distributed by: